欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2022, Vol. 27 ›› Issue (11): 1285-1291.doi: 10.12092/j.issn.1009-2501.2022.11.011

• 医院药学之窗 • 上一篇    下一篇

老年医学科冠心病患者抗血小板药物服用情况的调查分析

卢希娅1,2,李玉星1,2,李文智1,2,彭园园1,胡 宜1,2,万 李1,2,陈碧莲1   

  1. 1中南大学湘雅医院老年医学科,长沙 410078,湖南;2中南大学湘雅医院全科医学,长沙 410078,湖南
  • 收稿日期:2022-08-25 修回日期:2022-09-26 出版日期:2022-11-26 发布日期:2022-12-12
  • 通讯作者: 陈碧莲,女,博士,主任医师,硕士生导师,研究方向:老年心血管疾病。 E-mail:1281373573@qq.com
  • 作者简介:卢希娅,女,本科,医师,研究方向:老年心血管疾病。 E-mail:2641125248@qq.com
  • 基金资助:
    湖南省卫健委科研课题(20201525);湖南省科技厅科研课题(2022JJ70156);长沙市科技局科研课题(kq2202367)

Analysis of prescribing of antiplatelet drug in patients with coronary heart disease in department of geriatrics 

LU Xiya1,2, LI Yuxing1,2, LI Wenzhi1,2, PENG Yuanyuan1, HU Yi1,2, WAN Li1,2, CHEN Bilian1   

  1. 1Department of Geriatrics, Xiangya Hospital, Central South University, Changsha 410078, Hunan, China; 2Department of General Practice, Xiangya Hospital, Central South University, Changsha 410078, Hunan, China
  • Received:2022-08-25 Revised:2022-09-26 Online:2022-11-26 Published:2022-12-12

摘要: 目的:调查分析老年医学科冠心病患者不同抗血小板药物服用及其临床病情。方法:本研究为一项单中心横断面研究,选取2021年12月至2022年6月在中南大学湘雅医院老年医学科心血管亚专科住院的冠心病患者,调查分析患者单用或双联抗血小板药物服用情况和临床病情资料。结果:共纳入347例冠心病患者,年龄为(65.2±10.1)岁,氯吡格雷是服用率最高的抗血小板药物,且随着冠脉靶病变支数的增加,氯吡格雷服用率明显增加(P<0.05);双联抗血小板治疗(dual antiplatelet therapy, DAPT)方案中阿司匹林联合氯吡格雷应用最为广泛(P<0.05)。在靶血管病变支数不同的各组中,阿司匹林服用率均高于吲哚布芬(P<0.05);与服用阿司匹林的患者比较,服用吲哚布芬的患者年龄大,血肌酐水平高,合并慢性胃病比例高,血小板聚集率水平高(P<0.05)。结论:氯吡格雷在冠心病患者中是最常用的抗血小板药物;在DAPT中阿司匹林联合氯吡格雷服用率最高;与阿司匹林相比,在合并慢性胃炎、血肌酐水平高和高龄患者中吲哚布芬服用率明显增加。

关键词: 冠心病, 抗血小板药物, 阿司匹林, 吲哚布芬, 氯吡格雷, 替格瑞洛

Abstract:

AIM: To analyze the prescribing of different antiplatelet drugs and clinical conditions of patients with coronary heart disease in department of Geriatrics.  METHODS: This study was a single center and cross-sectional study. Patients with coronary heart disease were recruited when hospitalized in the department of Geriatrics department, Xiangya Hospital, Central South University between December 2021 and June 2022. We investigated and analyzed the clinical conditions of patients including the prescribing of the antiplatelet drugs. RESULTS: A total of 347 coronary heart disease patients with a mean age of (65.2±10.1) years were included. The antiplatelet drug clopidogrel was the most commonly prescribed. Among the different dual antiplatelet therapy (DAPT), aspirin combined with clopidogrel was the most widely used. With the increasing of the numbers of target coronary lesions, the prescribing rate of clopidogrel increased significantly (P<0.05). In three groups with different degrees of target coronary lesions, the prescribing rate of aspirin was higher than that of indobufene (P<0.05). Compared with patients taking aspirin, the patients taking indobufene were older with a higher blood creatinine level, a higher proportion of chronic gastropathy and the higher level of platelet aggregation rates (P<0.05). CONCLUSION: Clopidogrel is the most commonly prescribed antiplatelet drugs in patients with coronary heart disease. Aspirin combined with clopidogrel is the most widely used in DAPT. Compared with aspirin, indobufene is more commonly used in elderly patients with the chronic gastritis and a higher serum creatinine level.  

Key words: coronary heart disease, antiplatelet drug, aspirin, indobufene, clopidogrel, ticagrelor

中图分类号: